Norgine Limited – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 12 PAGES: 51

Norgine Limited – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Norgine Limited - Product Pipeline Review - H2 2011” provides data on the Norgine Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Norgine Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Norgine Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Norgine Limited - Brief Norgine Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Norgine Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Norgine Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Norgine Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Norgine Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Norgine Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Norgine Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows

More Info
									  Norgine Limited – Product Pipeline Review – H2 2011
                                                                                          Reference Code: GMDHC01765CDB

                                                                                                 Publication Date: NOV 2011




Norgine Limited – Product Pipeline Review – H2 2011                                         GMDHC01765CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Norgine Limited – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Norgine Limited Snapshot ........................................................................................................................................................................................ 6
      Norgine Limited Overview .................................................................................................................................................................................. 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
Norgine Limited – Research and Development Overview ......................................................................................................................................... 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
Norgine Limited – Pipeline Review ........................................................................................................................................................................... 9
      Pipeline Products by Stage of Development ....................................................................................................................................................... 9
      Pipeline Products – Monotherapy .....................................................................................................................................................................10
Norgine Limited – Pipeline Products Glance ............................................................................................................................................................11
      Norgine Limited – Late Stage Pipeline ..............................................................................................................................................................11
            Phase III Products/Combination Treatment Modalities ................................................................................................................................11
      Norgine Limited Clinical Stage Pipeline Products ..............................................................................................................................................12
            Phase II Products/Combination Treatment Modalities .................................................................................................................................12
      Norgine Limited–Early Stage Pipeline Products ................................................................................................................................................13
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................13
            Discovery Products/Combination Treatment Modalities ..............................................................................................................................14
Norgine Limited – Drug Profiles ...............................................................................................................................................................................15
      Cametor ............................................................................................................................................................................................................15
            Product Description ....................................................................................................................................................................................15
            Mechanism of Action...................................................................................................................................................................................15
            R&D Progress .............................................................................................................................................................................................15
      Drug for Hepato Protection................................................................................................................................................................................16
            Product Description ....................................................................................................................................................................................16
            Mechanism of Action...................................................................................................................................................................................16
            R&D Progress .............................................................................................................................................................................................16
      IBD Program .....................................................................................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................17
      Laxative Program ..............................................................................................................................................................................................18
            Product Description ....................................................................................................................................................................................18
            Mechanism of Action...................................................................................................................................................................................18
            R&D Progress .............................................................................................................................................................................................18
      NRL001.............................................................................................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
Norgine Limited – Pipeline Analysis .........................................................................................................................................................................20
      Norgine Limited – Pipeline Products by Therapeutic Class ................................................................................................................................20
      Norgine Limited - Pipeline Products By Target ..................................................................................................................................................21
      Norgine Limited – Pipeline Products by Route of Administration........................................................................................................................22
      Norgine Limited – Pipeline Products by Molecule Type .....................................................................................................................................23




Norgine Limited – Product Pipeline Review – H2 2011                                                                                                         GMDHC01765CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Norgine Limited – Product Pipeline Review



Norgine Limited - Dormant Projects .........................................................................................................................................................................24
Norgine Limited – Company Statement ...................................................................................................................................................................25
Norgine Limited – Locations And Subsidiaries .........................................................................................................................................................26
      Head Office .......................................................................................................................................................................................................26
      Other Locations & Subsidiaries .........................................................................................................................................................................26
Recent Developments .............................................................................................................................................................................................27
            Jan 30, 2004: Takeda Exercises Rights To Licence To Develop Alizyme's Obesity Drug For Japan ...........................................................27
            Dec 22, 2008: Takeda Starts Phase 3 Clinical Studies Of ATL-962 A Treatment For Obesity And Related Diseases In Japan ...................28
Financial Deals Landscape......................................................................................................................................................................................29
      Norgine Limited, Deals Summary ......................................................................................................................................................................29
Norgine Limited, Pharmaceuticals & Healthcare, Deal Details .................................................................................................................................30
      Asset Transactions......................
								
To top